Top Markets
Coin of the day
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Clasificación en acciones #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Precio por acción
$0.6379482
Última sincronización: 2023-05-22
Capitalización bursátil
$5.98M
Cambio (1 día)
-0.44%
Cambio (1 año)
0.00%
País
FR
Comercio Nicox S.A. (COX)

Categoría

EPS de Nicox S.A. (COX)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Nicox S.A., el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Nicox S.A. desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras
Empresa EPS Diferencia de EPS País
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE